<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Failure to thrive in older adults: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Failure to thrive in older adults: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Failure to thrive in older adults: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn Agarwal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eduardo Bruera, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Failure to thrive (FTT) describes a syndrome of global decline. The United States National Institute of Aging described FTT as a "syndrome of weight loss, decreased appetite and poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low cholesterol" [<a href="#rid1">1</a>]. FTT in older adults may represent a final common pathway toward death unless interventions can reverse the course.</p><p>For some patients, FTT is caused by a single disease (eg, cancer) and the treatment of that disease drives the management plan. However, in many cases, multiple factors such as medical comorbidities, medications, and psychological factors contribute to impairment. Identifying and treating these contributing factors can change the course of illness, improve quality of life and function in this group of older adults; such treatment should be instituted as appropriate and in keeping with the patient's goals of care.</p><p>This topic will present an overview of the management of older adult patients with FTT. Evaluation of older patients with suspected FTT, including evaluation of potentially reversible causes, and an overview of management of the older adult resident in a long-term care facility are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3018.html" rel="external">"Failure to thrive in older adults: Evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/3011.html" rel="external">"Medical care in skilled nursing facilities (SNFs) in the United States"</a>.)</p><p class="headingAnchor" id="H1269887013"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Failure to thrive (FTT) is a somewhat confusing term that has been used to describe patients with varied clinical scenarios. In some circumstances, the diagnosis is given upon initial evaluation of a patient in decline who has subsequent identification of a treatable illness (eg, depression, grief, thyroid disorder). In this situation, the diagnosis of FTT is no longer useful and the underlying condition should be treated. It is important that all patients with a FTT diagnosis receive a thorough workup for treatable conditions, rather than a preemptive palliative approach. (See  <a class="medical medical_review" href="/z/d/html/3018.html" rel="external">"Failure to thrive in older adults: Evaluation"</a>.)</p><p>Other patients with FTT include those in decline despite optimal management of a chronic or terminal illness (eg, congestive heart failure, chronic obstructive pulmonary disease, cancer, dementia), or those with symptoms of global decline but no causative illness despite appropriate workup. We suggest that both of these patients can benefit from continued management of underlying chronic conditions as well as management of FTT symptoms.</p><p>For patients in continued decline despite maximal medical management of treatable conditions, or no definable cause of decline, a diagnosis of FTT marks an appropriate time for the clinician to engage patients and families/other loved ones in discussions about goals of care. A frank evaluation of the relative benefits of life-prolonging versus comfort-oriented treatment is appropriate, as FTT is a condition associated with considerable debility.</p><p>However, all patients have the potential for significant improvements in quality of life, even in the setting of a major disease states, by treating symptoms contributing to FTT.</p><p>The following measures are appropriate for all patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Enlist a multidisciplinary team (social worker; dietitian; dentist; physical, occupational, and speech therapists) to address symptom management as appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimize chronic medical illness management, including any new conditions which may be contributing to FTT (eg, reactivation tuberculosis, polymyalgia rheumatica, malignancy). This may involve more aggressive intervention or de-escalating interventions in light of worsening prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate and treat pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for potentially reversible causes of FTT (eg, medication side effect, depression, thyroid disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review medications with the following considerations (see  <a class="medical medical_review" href="/z/d/html/3013.html" rel="external">"Drug prescribing for older adults"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medications with the potential to cause drowsiness or lethargy may cause symptoms of FTT. For example, patients who are have previously tolerated stable doses of chronic narcotics may experience increased side effects as they decline, and they may exhibit symptoms of FTT due to oversedation. Reducing the dose or eliminating sedating medications can have a significant beneficial effect on functional status and nutrition.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identify and discontinue medications taken for long-term health benefits that are beyond the patient's life expectancy (eg, statins for cardiovascular disease prevention).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjust medication doses to the lowest effective dose in order to lessen adverse side effects. Attention to dose adjustments is especially important for patients with FTT due to changes in pharmacokinetics secondary to progressive renal failure or hypoalbuminemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Address polypharmacy in terms of overall number of medications, as well as the timing and the frequency of dosing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identify and discontinue medications inappropriate for older adults, if possible. In particular, those with anticholinergic properties  (<a class="graphic graphic_table graphicRef100289" href="/z/d/graphic/100289.html" rel="external">table 1</a>) should be discontinued due to their association with voiding difficulties and cognitive decline [<a href="#rid2">2</a>]. Several criteria sets, including Beers Criteria [<a href="#rid3">3</a>] and Assessing Care of Vulnerable Elderly (ACOVE) indicators, have identified potentially inappropriate medications for older individuals  (<a class="graphic graphic_table graphicRef73834" href="/z/d/graphic/73834.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate patients with end-stage FTT for recurrent infections and development of pressure-induced skin and soft tissue injuries. (See  <a class="medical medical_review" href="/z/d/html/2884.html" rel="external">"Epidemiology, pathogenesis, and risk assessment of pressure-induced skin and soft tissue injury", section on 'Malnutrition'</a>.)</p><p></p><p class="headingAnchor" id="H1294790444"><span class="h1">SYMPTOM MANAGEMENT</span><span class="headingEndMark"> — </span>Approaches to the key failure to thrive (FTT) symptoms of weight loss, physical frailty, and neuropsychological impairment are discussed below. For any given patient, the decision of whether to initiate specific treatments is largely based on the preferences of the patient and their family or other loved ones in consideration with the overall goals of care. For the majority of the approaches below, there is little evidence supporting their efficacy, although for some there is evidence of potential harm, and these should be avoided. Patient preference is also an important factor in the decision to discontinue treatments which are only marginally effective or have become burdensome.</p><p class="headingAnchor" id="H4"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>Key features of FTT include weight loss and malnutrition, the causes of which are often multifactorial  (<a class="graphic graphic_table graphicRef54156" href="/z/d/graphic/54156.html" rel="external">table 3</a>). Although weight loss may not be reversible, all patients can benefit from efforts to address decreased food intake, with the goal of improving quality of life and potentially increasing weight.</p><p class="headingAnchor" id="H1073317863"><span class="h3">Approaches for increasing food intake</span><span class="headingEndMark"> — </span>Efforts to improve food intake involve addressing mechanical, social, and dietary issues. Referral to a dietician for evaluation and treatment can help with nutrition management.</p><p class="bulletIndent1"><span class="glyph">●</span>Address dental issues such as oral pain and poor denture fit</p><p class="bulletIndent1"><span class="glyph">●</span>Assess dysphagia and provide an appropriate diet if present</p><p class="bulletIndent1"><span class="glyph">●</span>Provide assistance with feeding and optimize social support at mealtimes</p><p class="bulletIndent1"><span class="glyph">●</span>Eliminate unnecessary dietary restrictions such as low-salt or low-fat diets</p><p class="bulletIndent1"><span class="glyph">●</span>Provide appealing foods, vary texture and flavors, and use finger foods</p><p class="bulletIndent1"><span class="glyph">●</span>Offer frequent small meals and encourage the patient to eat when they choose to</p><p class="bulletIndent1"><span class="glyph">●</span>Decrease pill burden by reducing the number and frequency of medications</p><p class="bulletIndent1"><span class="glyph">●</span>Treat depression if appropriate</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Interventions of no or marginal benefit</span><span class="headingEndMark"> — </span>We suggest caution and limited use of the following interventions as they may have no or marginal benefits.</p><p class="headingAnchor" id="H218794898"><span class="h4">Caloric supplements</span><span class="headingEndMark"> — </span>The decision to use caloric supplements should be considered only after removal of dietary restrictions and after other causes of anorexia or dysphagia have been addressed. Subsequently, since both the data and harms are limited, the decision to use of caloric supplements should be based on patient and family or other loved ones' preferences, with considerations of the financial burden and possible intolerance due to diarrhea or nausea. Although oral nutritional supplements (low-volume, high-calorie drinks or puddings) may add protein and calories, the overall benefit is not clear.</p><p class="bulletIndent1"><span class="glyph">●</span>The American Geriatrics Society's "Choosing Wisely" initiative advises to avoid the use of high-calorie supplements for treatment of cachexia in older adults because they do not improve quality of life, mood, functional status, or survival [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of trials in older adults, protein and energy supplements yielded a 2.2 percent gain in weight and a small mortality benefit among those who were undernourished but no improvement in function or decrease in hospital length of stay [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h4">Appetite stimulants</span><span class="headingEndMark"> — </span>The best-studied appetite stimulants are <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> and <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a>. The 2019 Updated Beers Criteria recommends avoiding megestrol acetate due to the unfavorable risk to benefit ratio [<a href="#rid3">3</a>]. The American Geriatrics Society (AGS) "Choosing Wisely" campaign recommends not using megestrol acetate due to lack of improvement in quality of life or survival and the increased risk of thrombotic events, fluid retention, and death [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults", section on 'Appetite stimulants'</a>.)</p><p><a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">Cyproheptadine</a> is also used as an appetite stimulant but is not recommended by the AGS "Choosing Wisely" campaign or the 2019 Beers Criteria.</p><p>Appetite stimulants in patients with anorexia or cachexia are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Physical frailty</span><span class="headingEndMark"> — </span>Recommendations regarding treatments for physical frailty are mostly made in the context of patients who are frail but more robust than those with FTT. In frail older adults, four interventions (exercise [resistance and aerobic]), vitamin D supplementation, caloric and protein support, and reduction of polypharmacy are recommended [<a href="#rid6">6</a>]. Frailty is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3010.html" rel="external">"Frailty"</a>.)</p><p class="headingAnchor" id="H9492888"><span class="h3">Exercise</span><span class="headingEndMark"> — </span>Exercise, including strength and aerobic training, improves functional outcomes and prevents disability in older adults [<a href="#rid7">7-9</a>] and attenuates the impact of age on mortality [<a href="#rid10">10</a>]. Discussions of exercise for older adults can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16524.html" rel="external">"Physical activity and exercise in older adults"</a> and  <a class="medical medical_review" href="/z/d/html/116613.html" rel="external">"Practical guidelines for implementing a strength training program for adults", section on 'Important considerations for strength training in older adult patients'</a>.)</p><p>For patients with FTT, exercise may play a role, although clinicians should recognize that patients who are preterminal may not be able to exercise, and other patients may not wish to do so. Referral to physical therapy for evaluation and treatment is a key step in an exercise intervention.</p><p>Progressive resistance training (PRT) is the best-studied form of exercise for sarcopenia (age-related muscle loss). Resistance exercise among frail nursing home patients increases muscle mass, gait speed, and exercise tolerance [<a href="#rid11">11</a>]. Families and other loved ones should be counseled about ongoing strength and aerobic training or continued PRT after physical therapy treatment has finished.</p><p class="headingAnchor" id="H3139910350"><span class="h3">Vitamin D</span><span class="headingEndMark"> — </span>Patients with FTT are at risk for sarcopenia. For patients with sarcopenia and low vitamin D levels (&lt;20 ng/mL measured by a 25-hydroxyvitamin D test), Vitamin D supplementation is not recommended to improve sarcopenia alone, but we would consider a trial of therapy on an individual basis for patients with FTT since there is no robust evidence of benefit or harm in this population [<a href="#rid12">12</a>]. For older patients without sarcopenia, the value of treating low vitamin D levels to prevent falls, or to improve physical function, is questionable and is discussed in detail elsewhere [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">"Vitamin D and extraskeletal health"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Interventions to avoid</span><span class="headingEndMark"> — </span>We recommend not using growth hormone and anabolic agents in FTT due to lack of efficacy and detrimental side effects [<a href="#rid14">14-17</a>] (see  <a class="medical medical_review" href="/z/d/html/3010.html" rel="external">"Frailty", section on 'Ineffective interventions'</a>). The use of ghrelin, an amino-acid peptide which stimulates secretion of growth hormone, is not well studied in the population and is discussed elsewhere [<a href="#rid18">18-20</a>]. (See  <a class="medical medical_review" href="/z/d/html/5380.html" rel="external">"Ghrelin"</a>.)</p><p class="headingAnchor" id="H2403796742"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>FTT in patients with dementia, depression and those at the end of life have unique considerations.</p><p class="headingAnchor" id="H11"><span class="h3">Dementia</span><span class="headingEndMark"> — </span>Patients with dementia and FTT may benefit from increased environmental support, to assist with feeding and self-care, and increased social interaction. Some patients with dementia may stabilize and even improve when their living situation is changed to a higher level of assistance and supervision, such as in an assisted living facility or nursing home. (See  <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">"Management of the patient with dementia"</a>.)</p><p>Patients with advanced dementia lose the ability to chew, swallow, and manage their oral secretions. Providing food for comfort at this stage may be an option, although the risk of aspiration should be evaluated and considered. A discussion of oral versus tube feeding for patients with advanced dementia can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/86250.html" rel="external">"Care of patients with advanced dementia", section on 'Oral versus tube feeding'</a>.)</p><p>For patients with dementia who are depressed, the benefit of antidepressant therapy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia", section on 'Depression'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Depression</span><span class="headingEndMark"> — </span>Treatment of depression may result in marked improvement in FTT and potential reversal of symptoms. The mainstay of therapy for depression is antidepressant medication supplemented by structured psychotherapy, when appropriate.</p><p>Electroconvulsive therapy may be appropriate for older patients with severe depression. (See  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.)</p><p class="headingAnchor" id="H2811665011"><span class="h4">Antidepressants</span><span class="headingEndMark"> — </span>Antidepressant medications are chosen based on their desired side effect profile, as most agents are equally effective. In older patients with depressive symptoms, we would use <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> or a selective serotonin reuptake inhibitor (SSRI)/serotonin–norepinephrine reuptake inhibitor (SNRI) not associated with anorexia (eg, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) to treat depression and possibly assist with weight gain. <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> and the SSRIs <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> are more likely to cause anorexia and weight loss than other antidepressants [<a href="#rid21">21</a>]. Although tricyclic antidepressants may improve appetite more than SSRIs, they have significant anticholinergic side effects.</p><p><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> is known to have side effects of increased appetite and weight gain [<a href="#rid22">22</a>]. Although at least one case report has described efficacy in FTT [<a href="#rid23">23</a>], two studies comparing mirtazapine with other non-tricyclic antidepressants in depressed older nursing facility patients showed similar weight gain in both groups [<a href="#rid24">24,25</a>]. In general, the use of mirtazapine for treatment of unintended weight loss is not recommended in the absence of depression [<a href="#rid26">26</a>]. Depressed older adult patients who are wary of taking an antidepressant may be willing to try mirtazapine if it offered as an appetite stimulant rather than an antidepressant. (See  <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">"Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Mirtazapine'</a>.)</p><p class="headingAnchor" id="H13"><span class="h4">Psychostimulants</span><span class="headingEndMark"> — </span>Severely depressed and medically ill older adults are sometimes treated with psychostimulants such as <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> to rapidly improve the symptoms of depression. There is limited evidence to support use of psychostimulants to improve food intake. However, in patients with significant apathy symptoms it may be worthwhile to attempt a brief trial of low-dose methylphenidate with caution to monitor for side effects [<a href="#rid27">27-29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of 129 medically ill geriatric patients given <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> or <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a> for depression, 81 percent demonstrated some improvement, starting on the second day of treatment [<a href="#rid30">30</a>]. Only 8 percent had to stop the drug trial due to adverse side effects.</p><p></p><p>Although psychostimulants are not considered appetite stimulants, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> at low doses may improve apathy and give patients enough energy to eat and to participate in activities. However, methylphenidate at doses of 20 mg per day was associated with weight loss in patients with dementia [<a href="#rid31">31</a>].We suggest that if methylphenidate is used, it should be initiated cautiously at small doses, starting typically with 2.5 mg in the morning and titrating slowly.</p><p class="headingAnchor" id="H3770020854"><span class="h1">HOSPICE</span><span class="headingEndMark"> — </span>Failure to thrive (FTT) may represent a final common pathway toward death unless interventions can reverse the course. Even with the best of care, a patient's weight loss and functional decline may not be amenable to interventions or may not improve depending on the underlying disease state and comorbidities. As FTT in the older adult progresses, it is important to consider a focus on palliative care.</p><p>FTT and debility are no longer diagnoses used for enrollment in hospice; in April 2013, the Centers for Medicare and Medicaid Services (CMS) indicated that FTT or debility are not primary diagnoses for hospice admission; rather, hospices should bill for the primary disease state as the principal diagnosis [<a href="#rid32">32</a>]. However, the prognosis for any disease state will be worse if the patient meets criteria for clinical decline. Frequently used criteria for determining non-disease-specific decline in clinical status that correlate with a six-month prognosis may include [<a href="#rid33">33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss not due to reversible causes</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent or intractable infections</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent aspiration and/or inadequate oral intake due to intractable dysphagia</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive decline in Karnofsky Performance status</p><p class="bulletIndent1"><span class="glyph">●</span>Progressing dementia by objective measures</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive pressure ulcers (stage 3 or 4) despite optimal care</p><p></p><p>Since hospice can provide support and benefits for patients with FTT who are approaching the end of life, consultation with a local hospice organization or palliative care specialist may be helpful in determining eligibility. (See  <a class="medical medical_review" href="/z/d/html/2200.html" rel="external">"Hospice: Philosophy of care and appropriate utilization in the United States"</a>.)</p><p>Other issues related to end-of-life care are discussed separately in multiple topics in UpToDate. (See  <a class="medical medical_review" href="/z/d/html/2202.html" rel="external">"Ethical issues in palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/2207.html" rel="external">"Legal aspects in palliative and end-of-life care in the United States"</a> and  <a class="medical medical_review" href="/z/d/html/2196.html" rel="external">"Approach to symptom assessment in palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/14244.html" rel="external">"Stopping nutrition and hydration at the end of life"</a> and  <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">"Overview of managing common non-pain symptoms in palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">"Overview of comprehensive patient assessment in palliative care"</a>.)</p><p class="headingAnchor" id="H1456450726"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/141278.html" rel="external">"Patient education: Malnutrition (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/141279.html" rel="external">"Patient education: Malnutrition – Discharge instructions (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Management of failure to thrive (FTT) as outlined above is appropriate for patients in whom reversible causes of decline have been evaluated and treated. (See <a class="local">'Introduction'</a> above and <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing goals of care</strong> – A diagnosis of FTT may be considered as a critical point for evaluation of the patient's overall goals of care. A frank discussion of the relative benefits of life-prolonging versus comfort-oriented treatment is appropriate. Aggressive interventions should be approached cautiously in the face of declining functional status and worsening prognosis. However, all patients have the potential to benefit from interventions to improve quality of life. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidisciplinary approach</strong> – Treatment for FTT may involve enlisting a multidisciplinary team (eg, social worker, dietitian, dentist, physical, occupational, and speech therapists) as needed to address contributing factors. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to weight loss</strong> – For patients with weight loss, interventions to increase food intake include assistance with feeding, discontinuation of dietary restrictions, addressing oral and swallowing issues, and providing social support at mealtimes. Referral to a dietician for evaluation and treatment can help with nutrition management. (See <a class="local">'Approaches for increasing food intake'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If diet interventions have failed to improve food intake, the use of caloric supplements can be considered be based on patient and family/other loved ones' preferences, in light of the financial burden and possible intolerance due to diarrhea or nausea. (See <a class="local">'Caloric supplements'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We agree with guidelines for older adults that recommend avoiding appetite stimulants (<a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> or <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a>) since these drugs have marginal benefit and potential side effects. (See <a class="local">'Appetite stimulants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of physical frailty</strong> – For patients with physical frailty, progressive resistance training (PRT) or strength and aerobic training can improve functional outcomes, if they are able to exercise. (See <a class="local">'Physical frailty'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treating depression</strong> – For patients with depression, treatment can improve appetite. Antidepressants differ in their impact on appetite and weight and, when a trial of antidepressants is initiated, the choice of antidepressant should include consideration of their side effect profile. In older patients with both depressive symptoms and weight loss, we would prescribe <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> or a selective serotonin reuptake inhibitor (SSRI)/serotonin–norepinephrine reuptake inhibitor (SNRI) not associated with anorexia (eg, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>). (See <a class="local">'Antidepressants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe depression, a psychiatry consultation is indicated for consideration of other therapies, hospitalization, and/or electroconvulsive therapy. (See <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with dementia</strong> – Patients with advanced dementia lose the ability to chew, swallow, and manage their oral secretions. Providing food for comfort at this stage may be an option, although the risk of aspiration should be evaluated and considered. (See <a class="local">'Dementia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palliative approach for some patients</strong> – As FTT advances, a palliative care approach should be considered, including hospice evaluation. (See <a class="local">'Hospice'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sarkisian CA, Lachs MS. "Failure to thrive" in older adults. Ann Intern Med 1996; 124:1072.</a></li><li><a class="nounderline abstract_t">Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56:2203.</a></li><li><a class="nounderline abstract_t">By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2019; 67:674.</a></li><li class="breakAll">http://www.choosingwisely.org/clinician-lists/american-geriatrics-society-prescription-appetite-stimulants-to-treat-anorexia-cachexia-in-elderly/ (Accessed on November 26, 2018).</li><li><a class="nounderline abstract_t">Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2009; :CD003288.</a></li><li><a class="nounderline abstract_t">Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14:392.</a></li><li><a class="nounderline abstract_t">Binder EF, Schechtman KB, Ehsani AA, et al. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc 2002; 50:1921.</a></li><li><a class="nounderline abstract_t">LIFE Study Investigators, Pahor M, Blair SN, et al. Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci 2006; 61:1157.</a></li><li><a class="nounderline abstract_t">Daniels R, van Rossum E, de Witte L, et al. Interventions to prevent disability in frail community-dwelling elderly: a systematic review. BMC Health Serv Res 2008; 8:278.</a></li><li><a class="nounderline abstract_t">Hubbard RE, Fallah N, Searle SD, et al. Impact of exercise in community-dwelling older adults. PLoS One 2009; 4:e6174.</a></li><li><a class="nounderline abstract_t">Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330:1769.</a></li><li><a class="nounderline abstract_t">Dent E, Morley JE, Cruz-Jentoft AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging 2018; 22:1148.</a></li><li><a class="nounderline abstract_t">Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. JAMA Intern Med 2016; 176:175.</a></li><li><a class="nounderline abstract_t">Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146:104.</a></li><li><a class="nounderline abstract_t">Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology 2014; 60:294.</a></li><li><a class="nounderline abstract_t">Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299:39.</a></li><li><a class="nounderline abstract_t">Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc 2008; 56:1991.</a></li><li><a class="nounderline abstract_t">Lundholm K, Gunnebo L, Körner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010; 116:2044.</a></li><li><a class="nounderline abstract_t">Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149:601.</a></li><li class="breakAll">http://clinicaltrials.gov/ct2/show/NCT01898611 (Accessed on March 05, 2014).</li><li><a class="nounderline abstract_t">Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53:842.</a></li><li><a class="nounderline abstract_t">Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7:249.</a></li><li><a class="nounderline abstract_t">Schillerstrom JE, Seaman JS. Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient. Int J Psychiatry Med 2002; 32:405.</a></li><li><a class="nounderline abstract_t">Goldberg RJ. Weight change in depressed nursing home patients on mirtazapine. J Am Geriatr Soc 2002; 50:1461.</a></li><li><a class="nounderline abstract_t">Mihara IQ, McCombs JS, Williams BR. The impact of mirtazapine compared with non-TCA antidepressants on weight change in nursing facility residents. Consult Pharm 2005; 20:217.</a></li><li><a class="nounderline abstract_t">Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy 2009; 29:383.</a></li><li><a class="nounderline abstract_t">Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2010; 18:371.</a></li><li><a class="nounderline abstract_t">Herrmann N, Rothenburg LS, Black SE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 2008; 28:296.</a></li><li><a class="nounderline abstract_t">Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry 2008; 69:1981.</a></li><li><a class="nounderline abstract_t">Pickett P, Masand P, Murray GB. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J Geriatr Psychiatry Neurol 1990; 3:146.</a></li><li><a class="nounderline abstract_t">Rosenberg PB, Lanctôt KL, Drye LT, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 2013; 74:810.</a></li><li class="breakAll">National Association for Home Care &amp; Hospice. Hospice Claims and Use of Debility, Adult Failure to Thrive, and Dementia Diagnoses. Homecare &amp; Hospice website, Mary 2013. Available at: http://www.nahc.org/NAHCReport/nr130509_1/ (Accessed on October 22, 2013).</li><li class="breakAll">National Gerontological Nurses Association Website. http://www.ngna.org/resources/clinical-fast-facts/64-facilitating-the-transition-to-hospice-care.html (Accessed on April 29, 2011).</li></ol></div><div id="topicVersionRevision">Topic 3015 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633822" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : "Failure to thrive" in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19093918" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cumulative anticholinergic exposure is associated with poor memory and executive function in older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30693946" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Geriatrics Society 2019 Updated AGS Beers Criteria®for Potentially Inappropriate Medication Use in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30693946" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : American Geriatrics Society 2019 Updated AGS Beers Criteria®for Potentially Inappropriate Medication Use in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370584" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Protein and energy supplementation in elderly people at risk from malnutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764209" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Frailty consensus: a call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473001" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167156" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19115992" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Interventions to prevent disability in frail community-dwelling elderly: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584926" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of exercise in community-dwelling older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190152" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Exercise training and nutritional supplementation for physical frailty in very elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30498820" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747333" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227934" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Systematic review: the safety and efficacy of growth hormone in the healthy elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24731978" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18167405" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18795988" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20186829" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981485" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981485" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12096167" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Body weight changes associated with psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11607047" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A review of the pharmacological and clinical profile of mirtazapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12779190" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165011" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Weight change in depressed nursing home patients on mirtazapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16548628" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The impact of mirtazapine compared with non-TCA antidepressants on weight change in nursing facility residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323618" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220576" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Methylphenidate for apathy and functional status in dementia of the Alzheimer type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480686" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203481" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Stimulant treatment of frontotemporal dementia in 8 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2282130" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Psychostimulant treatment of geriatric depressive disorders secondary to medical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021498" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
